Abstract
with high phospho-ALK levels treatedwith crizotinib achieved partial responses; two cases with low phospho-ALK levels had progressive or stable disease. Discussion. ALK rearrangements and EGFR mutations were not mutually exclusive in NSCLC. Advanced pulmonary adenocarcinomas with such co-alterations could have diverse responses to EGFR-TKIs and crizotinib. Relative phospho-ALK and phospho-EGFR levels could predict the efficacy of EGFRTKI and ALK-TKI treatment. Funding. Financial support was provided by the following grants: National Natural Science Foundation of China Grants No. 81071699 (to X. Zhang) and No. 30772531 (to Y. Wu) and No. 81172090 (to Q. Zhou); Guangzhou Science andTechnology Project No. 11BppZXaa6040020 (to Y. Wu); Wu Jieping Medical Foundation special for Tumor Targeted Therapy Research. No. 3206720.10001 (to Q. Zhou). The authors declared no conflicts of interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
